Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
21 September 2018Website:
http://www.ymabs.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 21:22:13 GMTDividend
Analysts recommendations
Institutional Ownership
YMAB Latest News
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Peter Pfreundschuh as Chief Financial Officer, effective June 28, 2024. Mr. Pfreundschuh will report to Mike Rossi, President and Chief Executive Officer.
PHILADELPHIA, PA / ACCESSWIRE / June 14, 2024 / Kaskela Law LLC announces that it is investigating Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) ("Y-mAbs") on behalf of the company's long-term shareholders. Recently an amended securities fraud complaint was filed against Y-mAbs on behalf of certain investors who purchased shares of the company's stock between October 6, 2020, and October 28, 2022.
NEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that preclinical GD2-SADA data will be presented at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2024 Annual Meeting taking place June 8 – 11, 2024, in Toronto, Canada.
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Norman LaFrance, M.D. as Chief Development Officer.
The Company is scheduled to hold a conference call and webcast on Wednesday, May 8, 2024 at 8:00 a.m. ET.
The average of price targets set by Wall Street analysts indicates a potential upside of 31.3% in YmAbs Therapeutics (YMAB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
YmAbs Therapeutics (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
The consensus price target hints at a 31.4% upside potential for Y-mAbs Therapeutics, Inc. (YMAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Does Y-mAbs Therapeutics, Inc. (YMAB) have what it takes to be a top stock pick for momentum investors? Let's find out.
Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to earnings of $0.03 per share a year ago.
- 1(current)
What type of business is Y-mAbs Therapeutics?
Y-mAbs Therapeutics Inc is a commercial biopharmaceutical company. It is primarily engaged in the development and commercialization of new therapeutic products based on antibodies for the treatment of cancer. Its portfolio includes Naxitamab, Omburtamab, GD2-GD3 vaccine, and others. Y-mAbs Therapeutics, Inc. was founded in 2015, and its headquarters is located in New York, New York.
What sector is Y-mAbs Therapeutics in?
Y-mAbs Therapeutics is in the Healthcare sector
What industry is Y-mAbs Therapeutics in?
Y-mAbs Therapeutics is in the Biotechnology industry
What country is Y-mAbs Therapeutics from?
Y-mAbs Therapeutics is headquartered in United States
When did Y-mAbs Therapeutics go public?
Y-mAbs Therapeutics initial public offering (IPO) was on 21 September 2018
What is Y-mAbs Therapeutics website?
https://www.ymabs.com
Is Y-mAbs Therapeutics in the S&P 500?
No, Y-mAbs Therapeutics is not included in the S&P 500 index
Is Y-mAbs Therapeutics in the NASDAQ 100?
No, Y-mAbs Therapeutics is not included in the NASDAQ 100 index
Is Y-mAbs Therapeutics in the Dow Jones?
No, Y-mAbs Therapeutics is not included in the Dow Jones index
When does Y-mAbs Therapeutics report earnings?
The next expected earnings date for Y-mAbs Therapeutics is 09 August 2024